摘要
目的探讨乙肝新疗法与ＢＣＧ、潘生丁联合抗ＨＢＶ的作用。方法选择ＨＢｅＡｇ阳性乙肝病人５１２例，１∶２０００ＯＴ试验局部红肿、硬结＜７ｍｍ者，于三角肌外侧皮内注射卡介苗（ＢＣＧ）０．１ｍｌ，每月１次。同时口服潘生丁５０ｍｇ，２次／ｄ，连用４～８个月，治疗前后进行肝功、乙肝５项标志物检测。结果症状体征改善多优于９０例的对照组。ＨＢｓＡｇ阴转率和ＨＢｓＡｂ阳转率：治疗组分别为５．４７％与８．２０％；对照组为５．５６％与９．８６％，差异无显著性。ＨＢｅＡｇ阴转率与ＨＢｅＡｂ阳转率：治疗组分别为６０．３５％与３１．６２％；对照组分别为１３．３３％与１２．９９％，差异非常显著（Ｐ＞０．０１）。结论研究结果提示两药联用有协同抗ＨＢＶ作用，从而达到可靠地控制ＨＢＶ和改善肝功能效果，而无严重不良反应发生。
Objective To investigate the new therapy of hepatitis B and the new uses of BCG and dipyridamole.Methods 512 patients with positive HBeAg were given BCG 0.1 ml intracutaneously outside the deltoid muscle once a month,and simultaneously took dipyridamole 50 mg twice a day for 4 to 8 months.The hepatic function and HBV marks were examined before and ofter such treatment.Results The improvement of the symptoms and signs in the treatment group were superior to those in the control group of 90 cases. The transformation rates of negative reaction of HBsAg and the transformation rates of positive reaction of HBsAb were 5.47% and 8.20% in the treatment group vs.5.56% and 9.86% in the control group,with no significant difference, while the transformation rates of negative reaction of HBeAg and the thansformation rates of positive reaction of HBeAb were 60.35% and 31.62% in the treatment group vs. 13.33% and 12.99% in the control group,with significant difference.Conclusion Having synergism in antiHBV,the two drugs can be simply and reliably used to control HBV and improve the hepatic function without serious untoward reactions occurred.
出处
《潍坊医学院学报》
1998年第1期33-34,共2页
Acta Academiae Medicinae Weifang
关键词
治疗
卡介苗
潘生丁
乙型肝炎
hepatitis ,HBV,man
treatment
BCG
dipyridamole
